Champions Oncology, Inc.

Champions Oncology, Inc.

$4.44
-0.12 (-2.63%)
NASDAQ Capital Market
USD, US
Biotechnology

CSBR Price Chart

Basic
Market Cap$65.39M
Price$4.54
52 Week Range3.6-7.13
Beta0.46
Margins
Gross Profit Margin44.27%
Operating Profit Margin-5.88%
Net Profit Margin-6.58%
Valuation (TTM)
P/E Ratio-17.77
Price to Sales Ratio1.17
Price to Book Ratio-181.80
PEG Ratio-0.33

Industry

Biotechnology

Sector

Healthcare

Full-Time Employees

210

IPO Date

2007-02-02T00:00:00.000Z

Description

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Phone

201 808 8400

Address

One University Plaza, Hackensack, NJ, 07601, US

CIK

0000771856